Quantcast

Industry news that matters to you.  Learn more

Archives for March 2012

Berg Diagnostics Receives CLIA Certification and Launches Novel Vitamin D Assay

Berg Diagnostics, a Boston-based molecular diagnostics company has received Massachusetts Clinical Laboratory Licensure and Certificate of Registration from the Centers for Medicare and Medicaid Services under the Clinical Laboratory Improvement Amendment (CLIA).

Karolinska Institutet Coordinates International Research on Neurodegenerative Diseases

Karolinska Institutet has been selected to coordinate a major EU research project on neurodegenerative diseases involving 22 countries and a total budget of over 90 million kronor.

Panel of Biomarkers Proves Useful in Predicting Chronic Heart Failure Outcomes

Critical Diagnostics, a biomarker company focused on cardiovascular diseases, recently announced positive results from a multi-center study in ambulatory heart failure patients, which confirmed that a contemporary panel of biomarkers, including ST2, was strongly predictive of risk and significantly improved the likelihood of identifying patients at risk for adverse events, compared to the most commonly used clinical risk score in heart failure, the Seattle Heart Failure Model (SHFM). The paper (“Multiple Biomarkers for Risk Prediction in Chronic Heart Failure”) was published online in Circulation: Heart Failure on February 23, 2012.

The CFIDS Association of America Breaks Ground on Its ‘Institute Without Walls’ to Transform Chronic Fatigue Syndrome Research

The CFIDS Association of America recently announced new additions to its comprehensive research initiative to advance objective diagnosis and effective treatment of chronic fatigue syndrome (CFS): five new grant awards, two new projects using resources from a central biobank and curation of a biomarker “hit list” to guide future research. The new investments total $2 million.

Parsortix Research Partnership with the Paterson Institute for Cancer Research

ANGLE plc (AIM: AGL) is pleased to announce that Parsortix Inc (“Parsortix”), its 90% owned portfolio company which specialises in cancer diagnostics, has signed a two year research agreement with the Cancer Research UK-funded Paterson Institute for Cancer Research, The University of Manchester’s world-leading cancer research institute.